Guoxin Securities released a research report on April 19 stating that Maiwei Biotech (688062.SH) was rated to increase its holdings. The main reasons for the rating include: 1) rapid growth in product sales; 2) commercialization of core products is progressing well. (Mainichi Keizai Shimbun)
国信证券4月19日发布研报称，给予迈威生物（688062.SH）增持评级。评级理由主要包括：1）产品销售快速增长；2）核心产品商业化推进良好。（每日经济新闻）
Guoxin Securities released a research report on April 19 stating that Maiwei Biotech (688062.SH) was rated to increase its holdings. The main reasons for the rating include: 1) rapid growth in product sales; 2) commercialization of core products is progre
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.